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| INTRODUCTION
The field of HIV vaccine research has been invigorated by the discovery of broadly neutralizing antibodies (bNAbs). While natural infection predominantly elicits non-neutralizing or strain-specific antibodies, 10-30% of HIV-infected individuals generate bNAbs approximately 2-4 years after infection. for up to 19 weeks. This was significant compared to historical controls that typically rebounded less than 3 weeks after treatment interruption. Taken together, these studies highlight the safety and efficacy of passive transfer of HIV bNAbs for reduction of viremia and maintenance of viral suppression. Given this demonstrable potency against HIV in humans, bNAbs may also serve as effective tools in the context of HIV prophylaxis. In fact, a phase II clinical trial sponsored by the NIAID Vaccine Research Center (VRC) is currently recruiting participants to evaluate the safety and efficacy of VRC01 passive transfer in preventing HIV infection in high-risk, uninfected women in SubSaharan Africa. 13 In addition, the VRC is recruiting participants for a phase I clinical trial to assess the safety of VRC01 passive transfer in infants less than 72 hours after birth at high risk for mother-to-child HIV transmission. shown to significantly improve antibody half-lives in vivo. [17] [18] [19] In the NHP model, passive transfer of VRC01 harboring these mutations (VRC01-LS) resulted in a longer serum half-life, increased antibody concentration at mucosal surfaces, and enhanced protection against SHIV challenge compared to the wildtype antibody. 20 A phase I clinical trial sponsored by the VRC is currently recruiting participants to assess the safety of passive transfer of VRC01-LS in healthy adults as the long-term immunogenicity of these engineered antibodies remains unknown. 21 Even considering the potential for longer intervals between doses, additional logistical requirements such as continual antibody production, temperature-controlled storage, and complex distribution networks, will further hinder the implementation of a passive transfer vaccine approach, particularly in developing countries where intervention is most needed. Therefore, other strategies must be explored for the generation of bNAb responses against HIV. (Fig. 1A) . Therefore, many studies have examined the co-evolution of HIV with bNAbs in order to identify unmutated common and early ancestor antibodies and understand the antigens that direct bNAb development. [33] [34] [35] [36] This could inform potential prime-boost vaccination strategies involving sequential immunogens to direct bNAb elicitation (Fig. 1B) . While such studies represent important conceptual advances for the field of immunogen design, these approaches would necessitate repeated administration, presenting challenges for patient compliance. In addition, the stochastic nature of antibody evolution and selection in each vaccine recipient makes it difficult to design regimens that will consistently and efficiently elicit bNAb responses in the vast majority of genetically diverse subjects.
| ANTIBODY GENE TRANSFER WITH ADENO-ASSOCIATED VIRAL VECTORS
As an alternative to traditional vaccination approaches, gene transfer has been used to produce HIV bNAbs in vivo. In this method, transgenes encoding the desired antibody are delivered to tissues, resulting in secretion and systemic expression of biologically active antibodies without the need for immunization (Fig. 1C) 
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In 2002, Lewis et al. 60 were the first to demonstrate the feasibil- 
| AAV-DELIVERED ANTIBODIES CONFER PROTECTION FROM HIV INFECTION
In 2009, Johnson et al. 64 were the first to demonstrate that AAV- A study by Fuchs et al. 70 showed that long-term expression of anti-SIV antibodies could protect from successive intravenous challenges of SIVmac239. They used two AAV vector approaches to deliver fulllength IgG1 antibodies derived from previously described SIV-specific immunoadhesin sequences. In the first approach, they used a traditional single-stranded rAAV vector to express the full-length antibody.
In the second approach, they used scAAV in which the heavy and light chain genes were delivered on separate vectors. IM injection of AAV led to variable serum concentrations with no discernable difference between the two vector approaches. Most macaques exhibited a precipitous drop in antibody concentration that coincided with the development of anti-antibody responses. However, one animal achieved a serum concentration of 270 μg/mL which persisted for more than 2 years in the absence of anti-antibody responses. Interestingly, this animal was the only one to resist six consecutive intravenous challenges with SIVmac239, the last of which was 10 intravenous infectious doses. While macaques with low-level antibody expression became infected, they did exhibit significantly lower SIV viral RNA during peak viremia and chronic phase infection. In addition, time from exposure to peak viremia was also significantly longer in these animals.
Lastly, Gardner et al. 71 Another potential area of concern is the prevalence of pre-existing immunity to AAV. Approximately, 60-70% of the human population is seropositive for antibodies against capsid for AAV1 and 2. 49 The presence of these antibodies would be predicted to significantly inhibit AAV transduction and thus reduce the efficacy of any AAV-based treatment. However, several strategies exist to address this issue.
| POTENTIAL PITFALLS OF AAV-VECTORED ANTIBODY GENE TRANSFER
First, a wide variety of AAV serotypes could be employed which have exhibited limited circulation in human populations. The AAV8 serotype was isolated from rhesus macaques and is advantageous for its propensity for muscle transduction, 73 reduced immunogenicity, 74 and lower prevalence of seropositive individuals (about 38%) in the population. 49 However, sufficient cross-reactivity between AAV capsids exist such that some individuals will still exhibit neutralizing activity against AAV8. While patient sera can be pre-screened for neutralizing factors prior to rAAV administration, new strategies will need to be developed to combat pre-existing immunity. Significant effort is being focused on the discovery of novel capsids that can improve tropism for tissues of One of the major issues that have arisen from AAV studies in NHP models has been the elicitation of anti-transgene immune responses that in some cases abolish efficacy against viral challenge. 64, 69, 70, 77 It is important to note, however, that none of the transgenes delivered in these studies were native macaque proteins, despite substantial effort to optimize the molecules for use in NHP.
For example, simianization of VRC07 was performed by transferring the complementarity-determining regions of human VRC07 onto homologous macaque germ line genes and engineering key somatic mutations within the framework regions. The heavy and light chain variable regions were then appended to macaque constant regions.
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While this simianized antibody maintained specificity and potency, it is uncertain how well it mimics native rhesus antibodies as it did not undergo immunological selection in macaques. Similarly, antibodies used by Fuchs et al. 70 were originally isolated by phage display and then converted into full-length simian antibodies, again skipping the key negative selection process. There is recent evidence that naturally elicited SIV-specific macaque antibodies isolated from NHP by means similar to human bNAbs exhibit substantially better expression characteristics in the absence of detectable anti-antibody responses following rAAV administration (HIV Keystone meeting 2016, Mario Roederer). As AAV-vectored antibody gene transfer will be used to deliver only fully human antibodies that underwent selection by the human immune system, we hypothesize that they will exhibit reduced immunogenicity than might have been predicted by published NHP studies. Importantly, individuals receiving infusions of VRC01 protein did not generate any detectable anti-antibody responses as long as 112 days post infusion. 10 Therefore, it is unclear whether antiantibody responses will be an area of concern in human patients.
While we do not believe that immunogenicity against the transgene will be widespread if rAAV/bNAb vectors are used at large, it is entirely possible that rare individuals may experience interactions that could not be predicted a priori. In these instances, it would be highly desirable to have a means of reversing antibody gene expres- 
| IMPROVING EXPRESSION AND EFFICACY OF AAV-DELIVERED BROADLY NEUTRALIZING ANTIBODIES
We and others are continually working to improve the efficacy of this protection is thought to correlate with high levels of ADCC. 91, 92 Additionally, HIV controllers have been shown to exhibit higher levels of ADCC-mediating antibodies compared to viremic subjects. 93 This interest in antibody-mediated effector functions has led to investigations of their contribution to the mechanism of bNAb-mediated protection.
In the NHP model, mutations abolishing effector function activity were engineered into the Fc region of b12. The mutated bNAb exhibited a significantly diminished capacity to prevent SHIV infection compared to wildtype b12 indicating a role for effector functions in protection.
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Similar results were observed using mutant human-mouse chimeric antibodies in a mouse model of HIV entry. 95 The relative importance of each effector function to bNAb efficacy and whether this contribution is similar across bNAbs of differing epitope specificity remains poorly understood. If Fc-mediated functions are shown to be important, then rAAV vectors can be used to deliver mutant bNAbs with enhanced effector function activity, potentially conferring protection superior to that of wildtype bNAbs and other available treatments. have not yet been published. The second trial sponsored by the VRC will test a rAAV8 vector expressing VRC07 in HIV-infected patients.
| CONCLUSION
Results from these studies will undoubtedly shed light on the present controversy surrounding anti-antibody responses and is likely to reveal other potential challenges that will need to be overcome to enable widespread use of antibody gene transfer in humans.
